An examination of the mechanisms driving the therapeutic effects of an AAV expressing a soluble variant of VEGF receptor-1
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0305466 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Seo Yun Moon und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of New Drug Development Research, CdmoGen Co., Ltd., Seoul, Korea. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-1, Dependovirus, Human Umbilical Vein Endothelial Cells, Vascular Endothelial Growth Factor A. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Drug Development Fund, Southwest Airlines.
Abstract (Originalsprache)
In previous animal model studies, we demonstrated the potential of rAAV2-sVEGFRv-1, which encodes a truncated variant of the alternatively spliced soluble version of VEGF receptor-1 (VEGFR1), as a human gene therapy for age-related macular degeneration (AMD) and diabetic retinopathy (DR). Here, we elucidate in vitro some of the mechanisms by which rAAV2-sVEGFRv-1 exerts its therapeutic effects. Human umbilical vein endothelial cells (HUVECs) were infected with rAAV2-sVEGFRv-1 or a control virus vector in the presence of members of the VEGF family to identify potential binding partners via ELISA, which showed that VEGF-A, VEGF-B, and placental growth factor (PlGF) are all ligands of its transgene product. In order to determine the effects of rAAV2-sVEGFRv-1 on cell proliferation and permeability, processes that are important to the progression AMD and DR, HUVECs were infected with the therapeutic virus vector under the stimulation of VEGF-A, the major driver of the neovascularization that characterizes the forms of these conditions most associated with vision loss. rAAV2-sVEGFRv-1 treatment, as a result, markedly reduced the extent to which these processes occurred, with the latter determined by measuring zonula occludens 1 expression. Finally, the human microglial HMC3 cell line was used to show the effects of the therapeutic virus vector upon inflammatory processes, another major contributor to angiogenic eye disease pathophysiology, with rAAV2-sVEGFRv-1 reducing therein the secretion of pro-inflammatory cytokines interleukin (IL)-1β and IL-6. Combined with our previously published in vivo data, the in vitro activity of the expressed transgene here further demonstrates the great promise of rAAV2-sVEGFRv-1 as a potential human gene therapeutic for addressing angiogenic ocular conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of New Drug Development Research, CdmoGen Co., Ltd., Seoul, Korea.
- CdmoGen Co., Ltd., Cheongju, Korea.
ORCID-Profile: Steven Hyun Seung Lee
Förderung
- Korea Drug Development Fund
- Southwest Airlines
Zitieren
APA
Moon, S. Y., Kim, H. J., Kim, J. K., Kim, J., Choi, J. S., Won, S. Y., Park, K., & Lee, S. H. S. (2024). An examination of the mechanisms driving the therapeutic effects of an AAV expressing a soluble variant of VEGF receptor-1. PLOS ONE. https://doi.org/10.1371/journal.pone.0305466
Vancouver
Moon SY, Kim HJ, Kim JK, Kim J, Choi JS, Won SY, et al. An examination of the mechanisms driving the therapeutic effects of an AAV expressing a soluble variant of VEGF receptor-1. PLOS ONE. 2024. doi:10.1371/journal.pone.0305466
BibTeX
@article{Moon2024,
author = {Moon, Seo Yun and Kim, Hee Jong and Kim, Jin Kwon and Kim, Jin and Choi, Jun-Sub and Won, So-Yoon and Park, Keerang and Lee, Steven Hyun Seung},
title = {An examination of the mechanisms driving the therapeutic effects of an AAV expressing a soluble variant of VEGF receptor-1},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0305466}
}
EUVIMED